好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

MoCA as a Measure of Cognitive Outcomes in Progressive Supranuclear Palsy (PSP)
Movement Disorders
P2 - Poster Session 2 (11:45 AM-12:45 PM)
3-007

To evaluate the longitudinal performance of the Montreal Cognitive Assessment (MoCA) as a measure of cognitive outcomes in progressive supranuclear palsy (PSP).
The MoCA is a widely recognized and well-validated assessment tool for the detection of mild cognitive impairment (MCI). Its brief and efficient administration presents a potential advantage over established outcome measures for PSP, such as the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). However, its effectiveness as a cognitive outcome measure in PSP has yet to be formally validated.

Cognitive assessment data, including the MoCA, RBANS, and PSP Rating Scale (PSPRS), from 162 participants diagnosed with PSP (mean age 69.1, 55% male) in the placebo arm of the Biogen PASSPORT study (NCT03068468) were analyzed using linear mixed-effects modelling (LMM) and repeated measures correlations (rmcorr).

LMM analysis reported a statistically significant time effect on the MoCA score over a 48-week period (p < 0.0001). At baseline, the estimated marginal mean (EMM) was 21.6 ± 0.5 (SE). By week 48, the EMM for the change in MoCA score was -1.4 ± 0.3 (SE). Small but significant changes were observed in all domains except abstraction. Over the same 48-week period, the MoCA correlated only weakly with the RBANS total scale (rmcorr = 0.1, p = 0.02), but exhibited a stronger correlation with the PSPRS (rmcorr = -0.22, p < 0.0001).

While the MoCA effectively identifies MCI at baseline and some decline over time, it appears to have limited sensitivity in capturing the specific and substantial cognitive decline associated with PSP. The correlation between the MoCA and the PSPRS could suggest that the MoCA is sensitive to motor and oculomotor dysfunction.

Authors/Disclosures
Vanessa Ibrahim
PRESENTER 		No disclosure on file
Catherine Isroff, MD (Mass General Hospital) Dr. Isroff has nothing to disclose.
Jay Iyer Mr. Iyer has nothing to disclose.
Ece Bayram, MD, PhD The institution of Dr. Bayram has received research support from National Institute on Aging (K99AG073453). The institution of Dr. Bayram has received research support from Lewy Body Dementia Association. The institution of Dr. Bayram has received research support from National Institute of Neurological Disorders and Stroke.
Leila Montaser-Kouhsari, MD, PhD (Stanford University) Dr. Montaser-Khousari has received personal compensation in the range of $0-$499 for serving as a Consultant for Darmyian, Trinity Life Sciences, Guidepoint and Techspert. Dr. Montaser-Khousari has received research support from DoD.
Matthew Swan, MD, FAAN The institution of Dr. Swan has received research support from Biogen. The institution of Dr. Swan has received research support from Sage Therapeutics. The institution of Dr. Swan has received research support from Parkinson's Foundation. The institution of Dr. Swan has received research support from Photopharmics. The institution of Dr. Swan has received research support from Denali Therapeutics. The institution of Dr. Swan has received research support from NOEMA Pharma.
Marian L. Dale, MD, FAAN (Oregon Health and Science University) Dr. Dale has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Dale has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Synergic Medical Technologies . Dr. Dale has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cognito Therapeutics. The institution of Dr. Dale has received research support from NIH . The institution of Dr. Dale has received research support from Collins Medical Trust.
Anthony E. Lang, MD, FAAN (Toronto Western Hospital) Dr. Lang has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AbbVie, Amylyx, Aprinoia, Biogen, BioAdvance, Biohaven, BioVie, BlueRock, BMS, Denali, Janssen, Lilly, Pharma 2B, Sun Pharma, and UCB. Dr. Lang has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for medicolegal cases related to paraquat. The institution of Dr. Lang has received research support from AbbVie. Dr. Lang has received intellectual property interests from a discovery or technology relating to health care. Dr. Lang has received publishing royalties from a publication relating to health care.
Lawrence I. Golbe, MD Dr. Golbe has received personal compensation in the range of $0-$499 for serving as a Consultant for Amylyx. Dr. Golbe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Aprinoia. Dr. Golbe has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ferrer. Dr. Golbe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitochon. Dr. Golbe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for IQVIA. Dr. Golbe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Woolsey. Dr. Golbe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ferrer. Dr. Golbe has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for Rossy Centre. Dr. Golbe has received intellectual property interests from a discovery or technology relating to health care. Dr. Golbe has received publishing royalties from a publication relating to health care. Dr. Golbe has a non-compensated relationship as a Chief Clinical Officer, Scientific Advisory Board Chair, Member of the Board of Directors, all as a volunteerd with CurePSP that is relevant to AAN interests or activities.
Doug Gunzler No disclosure on file
Anne Marie A. Wills, MD (MGH) Dr. Wills has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Accordant, a CVS/Caremark company. Dr. Wills has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi/Genzyme. The institution of Dr. Wills has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ono Pharmaceuticals. The institution of Dr. Wills has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. Dr. Wills has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Parkinson's Foundation. The institution of Dr. Wills has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx Pharmaceuticals. The institution of Dr. Wills has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ono Pharmaceuticals. The institution of Dr. Wills has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. The institution of Dr. Wills has received research support from Parkinson's Foundation. The institution of Dr. Wills has received research support from Biogen. The institution of Dr. Wills has received research support from Roche/Genentech. The institution of Dr. Wills has received research support from BioSensics.